STOCK MARKET BSE NSE

Sudden change of mind due to government pressure? Minutes show expert panel’s Covaxin somersault

After three meetings spread over four days, the subject expert committee of the Central Drugs Standards Control Organisation on Covid-19 recommended restricted emergency use for Covaxin.

Published: 06th January 2021 07:50 AM  |   Last Updated: 06th January 2021 11:10 AM   |  A+A-

'COVAXIN' was developed and manufactured at the company's Bio-safety Level-III high containment facility at Genome Valley.

'COVAXIN' was developed and manufactured at the company's Bio-safety Level-III high containment facility at Genome Valley.  (Photo| Special Arrangement)

Express News Service

NEW DELHI: A bare reading of the minutes of the three meetings the drug regulator’s expert panel held over the past week to consider accelerated licenses to coronavirus vaccines, indicates what was suspected all along — that the committee perhaps changed its mind on Covaxin overnight due to government pressure to clear a homegrown jab.

After three meetings spread over four days, the subject expert committee of the Central Drugs Standards Control Organisation on Covid-19 recommended restricted emergency use for Covishield by Serum Institute of India and Covaxin by Bharat Biotech-ICMR.

The approval to Covaxin, whose phase 3 trial on about 26,000 volunteers is still underway, however, led to a massive outcry in the scientific community as its efficacy is yet to be established.

ALSO READ | COVID-19: First vaccine jab by January 13?

The minutes of the SEC’s meetings on December 30 and January 1 show it was not satisfied with Covaxin’s phase 1 and 2 trial data alone, but changed its mind on January 2.

December 30’s minutes say that “after detailed deliberation, the committee recommended that the firm should update and present immunogenicity, safety and efficacy data for further consideration.”

On January 1, it recommended that Bharat Biotech expedite the recruitment of volunteers and perform interim efficacy analysis for further consideration. In the same meeting, the panel recommended Covishield’s approval. 

However, the very next day when an unscheduled meeting was held purportedly under pressure to clear the indigenous vaccine, Bharat Biotech presented further data and notably “requested for consideration of their proposal in the wake of incidence of new mutated coronavirus infection”.

Introducing the protection angle against the infectious UK virus strain perhaps gave the SEC legroom for its somersault. The minutes show the committee echoed Bharat Biotech, as it observed that Covaxin has the “potential to target mutated coronavirus strains”.

‘Covaxin data demonstrates strong immune response’

“The data generated so far demonstrates a strong immune response (both antibody as well as T cell) and in-vitro viral neutralisation,” the committee said, adding Bharat Biotech presented the safety and efficacy data from a non-human primate challenge study where the vaccine was found to be safe and effective.

ALSO READ | 6.3 lakh health workers to get first Covid vaccine jab in mid-January

“…after detailed deliberation, the committee recommended for grant of permission for restricted use in emergency situation in public interest as an abundant precaution, in clinical trial mode, to have more options for vaccinations especially in case of infection by mutant virus,” the panel noted.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp